

Date and Time: Wednesday 24th April 2013, 10:00-16:00

Minutes: Confirmed

Lipid Modification Guideline

Guideline Development Group Meeting 6

Place: Boardroom, National Clinical Guideline Centre
180 Great Portland Street, London W1W 5QZ

- | | | | |
|---------------------|----------------------------|---------------------------|---------------------------|
| GDG Present: | Anthony Wierzbicki (Chair) | (Present for notes 1 – 6) | |
| | Rajai Ahmad | (Present for notes 1 – 6) | |
| | Lindsay Banks | (Present for notes 1 – 6) | |
| | Liz Clark | (Present for notes 1 – 6) | |
| | Martin Duerden | (Present for notes 1 – 6) | |
| | Eleanor Grey | (Present for notes 1 – 6) | |
| | Michael Khan | (Present for notes 1 – 6) | |
| | Emma McGowan | (Present for notes 1 – 6) | |
| | Dermot Neely | (Present for notes 1 – 6) | |
| | Nadeem Qureshi | (Present for notes 1 – 6) | |
| | Alan Rees | (Present for notes 1 – 6) | |
| | David Wald | (Present for notes 1 – 6) | |
| | NCGC Present: | Lina Gulhane | (Present for notes 1 – 6) |
| | | Martin Harker | (Present for notes 1 – 6) |
| | | Norma O’Flynn | (Present for notes 1 – 6) |
| Silvia Rabar | | (Present for notes 1 – 6) | |

In attendance:

NICE Staff:	Clifford Middleton	
-------------	--------------------	--

Observers:

--	--	--

Agenda item

- Welcome introductions and apologies**
Anthony Wierzbicki welcomed the group to the sixth meeting of this GDG and thanked them for their time and commitment to the guideline. Apologies were received from David Wonderling and Angela Cooper.
- Declaration of Interests**
The Chair asked all GDG members to declare any new relevant conflicts of interest. The group then verbally declared the following new DOIs:

David Wald:

- Personal non-pecuniary interest: talk on FH.

Emma McGowan:

- Non-personal pecuniary interest: I am participating as a research nurse in an AMGEN Clinical trial. It includes a FH cohort of patients involving an injectable PCSK9 inhibitor.

Agenda item

3. **Review Question: For adults without established CVD (primary prevention) and with established CVD (secondary prevention) what is the clinical and cost effectiveness of statin therapy? Comparison of statins versus placebo**
The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist, NCGC) who gave a presentation on the clinical and cost effectiveness of statin therapy for the prevention of cardio-vascular disease, and took questions from the group. The GDG then discussed the evidence and discussed the strategy for further analysis. The Chair thanked Silvia Rabar and Martin Harker for their presentation.
4. **Review Question: Who is at risk of adverse effects from statin treatment?**
The GDG discussed the strategy for this review and agreed the inclusion criteria for it.
5. **Review Question: What is the clinical and cost effectiveness of phytosterol (stanol and sterol)-enriched foods or supplements versus placebo in primary and secondary prevention of CVD?**
The GDG agreed the review protocol for this review question
6. **Summary of next steps and any other business**
There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

Friday 31st May 2013, at NCGC.